)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Brainstorm Cell Therapeutics (BCLI) investor relations material
Brainstorm Cell Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary14 Aug, 2025
Executive summary
Management discussed ongoing business operations and future performance projections, focusing on neurodegenerative disorder treatments and the NurOwn technology platform, with NurOwn as the lead candidate for ALS, PMS, and AD.
FDA cleared initiation of the Phase 3b ENDURANCE trial for NurOwn in ALS, aiming for confirmatory data to support a potential BLA submission.
Clinical and regulatory progress continues, including FDA alignment on Phase 3b trial design and CMC aspects, and a new manufacturing partnership with Minaris Advanced Therapies.
Shares were delisted from Nasdaq and now trade on OTCQB Venture Market as of July 18, 2025.
NurOwn pharmacogenomic data was selected as Breakthrough Science at ISCT 2025, highlighting UNC13A genotype impact.
Financial highlights
Net loss for Q2 2025 was $2.9M, compared to $2.5M in Q2 2024; net loss for H1 2025 was $5.8M, down from $5.9M in H1 2024.
Net loss per share for Q2 2025 was $0.34 (vs. $0.60 in Q2 2024); for H1 2025, $0.77 (vs. $1.35 in H1 2024).
Cash, cash equivalents, and restricted cash totaled $1.03M at June 30, 2025.
Net cash used in operating activities for H1 2025 was $5.1M; net cash provided by financing activities was $5.8M.
Total assets were $2.57M and total liabilities $8.62M as of June 30, 2025, with a stockholders' deficit of $6.06M.
Outlook and guidance
Management expects continued operating losses and negative cash flow from clinical and regulatory activities, with additional capital required to fund trials and operations.
Focus remains on executing the clinical development plan for NurOwn, with ongoing engagement with clinical sites, CDMO partners, and the ALS community.
Anticipates the Phase 3b trial will generate data needed for a new BLA submission.
Uncertainty remains regarding the ability to raise future financing, especially after delisting from Nasdaq.
Assess capital resources for operations beyond 2025
Describe risks impacting forward-looking statements
Outline NurOwn's clinical development programs
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Brainstorm Cell Therapeutics earnings date
Q3 202518 Nov, 2025
Next Brainstorm Cell Therapeutics earnings date
Q3 202518 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Brainstorm Therapeutics Inc. engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage